{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Borgna F"],"funding":["horizon 2020 marie skłodowska-curie actions","net research foundation","cancer research foundation switzerland","PSI - Paul Scherrer Institute"],"pagination":["1113-1126"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8921065"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["49(4)"],"pubmed_abstract":["<h4>Purpose</h4>The β<sup>¯</sup>-emitting terbium-161 also emits conversion and Auger electrons, which are believed to be effective in killing single cancer cells. Terbium-161 was applied with somatostatin receptor (SSTR) agonists that localize in the cytoplasm (DOTATOC) and cellular nucleus (DOTATOC-NLS) or with a SSTR antagonist that localizes at the cell membrane (DOTA-LM3). The aim was to identify the most favorable peptide/terbium-161 combination for the treatment of neuroendocrine neoplasms (NENs).<h4>Methods</h4>The capability of the <sup>161</sup>Tb- and <sup>177</sup>Lu-labeled somatostatin (SST) analogues to reduce viability and survival of SSTR-positive AR42J tumor cells was investigated in vitro. The radiopeptides' tissue distribution profiles were assessed in tumor-bearing mi"],"journal":["European journal of nuclear medicine and molecular imaging"],"pubmed_title":["Combination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroendocrine neoplasms."],"pmcid":["PMC8921065"],"funding_grant_id":["701647","Petersen Investigator 2018","KFS-4678-02-2019-R"],"pubmed_authors":["Schibli R","van der Meulen NP","Borgna F","Zeevaart JR","Haller S","Grundler PV","Rodriguez JMM","Ginj M","Muller C","Koster U"],"additional_accession":[]},"is_claimable":false,"name":"Combination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroendocrine neoplasms.","description":"<h4>Purpose</h4>The β<sup>¯</sup>-emitting terbium-161 also emits conversion and Auger electrons, which are believed to be effective in killing single cancer cells. Terbium-161 was applied with somatostatin receptor (SSTR) agonists that localize in the cytoplasm (DOTATOC) and cellular nucleus (DOTATOC-NLS) or with a SSTR antagonist that localizes at the cell membrane (DOTA-LM3). The aim was to identify the most favorable peptide/terbium-161 combination for the treatment of neuroendocrine neoplasms (NENs).<h4>Methods</h4>The capability of the <sup>161</sup>Tb- and <sup>177</sup>Lu-labeled somatostatin (SST) analogues to reduce viability and survival of SSTR-positive AR42J tumor cells was investigated in vitro. The radiopeptides' tissue distribution profiles were assessed in tumor-bearing mi","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-04-04T20:50:30.796Z","creation":"2024-11-13T10:34:18.813Z"},"accession":"S-EPMC8921065","cross_references":{"pubmed":["34625828"],"doi":["10.1007/s00259-021-05564-0"]}}